David Masiello

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. doi request reprint Bendamustine therapy in chronic lymphocytic leukemia
    David Masiello
    USC Keck School of Medicine, Norris Cancer Center, Jane Ann Nohl Division of Hematology and Center for Blood Disease, Department of Medicine, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
    Expert Opin Pharmacother 10:1687-98. 2009
  2. pmc The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
    David Masiello
    Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California Medical Center, 1441 Eastlake Ave Suite 7317, Los Angeles, CA 90033, USA
    J Hematol Oncol 2:46. 2009
  3. ncbi request reprint Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer
    David Masiello
    Cancer Biology Program, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, 300 Brookline Avenue, Boston, MA 02215, USA
    Cancer Biol Ther 6:195-201. 2007
  4. pmc Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study
    Justin P Lee
    Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    J Hematol Oncol 2:30. 2009
  5. ncbi request reprint The gamma catenin/CBP complex maintains survivin transcription in β-catenin deficient/depleted cancer cells
    Yong mi Kim
    Childrens Hospital Los Angeles, Department of Pediatrics, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA
    Curr Cancer Drug Targets 11:213-25. 2011

Detail Information

Publications5

  1. doi request reprint Bendamustine therapy in chronic lymphocytic leukemia
    David Masiello
    USC Keck School of Medicine, Norris Cancer Center, Jane Ann Nohl Division of Hematology and Center for Blood Disease, Department of Medicine, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
    Expert Opin Pharmacother 10:1687-98. 2009
    ..Bendamustine is now approved in the US for the treatment of chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma, and is currently being explored in the treatment of several solid tumor types...
  2. pmc The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
    David Masiello
    Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California Medical Center, 1441 Eastlake Ave Suite 7317, Los Angeles, CA 90033, USA
    J Hematol Oncol 2:46. 2009
    ..Pleural effusions are generally managed by dose interruption/reduction and other supportive measures in patients with chronic myeloid leukemia receiving dasatinib therapy...
  3. ncbi request reprint Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer
    David Masiello
    Cancer Biology Program, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, 300 Brookline Avenue, Boston, MA 02215, USA
    Cancer Biol Ther 6:195-201. 2007
    ....
  4. pmc Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study
    Justin P Lee
    Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    J Hematol Oncol 2:30. 2009
    ..Our study was undertaken to examine the demographic and clinical features of chronic myelogenous leukemia (CML) patients presenting initially at the LAC+USC Medical Center, which serves an ethnically diverse population...
  5. ncbi request reprint The gamma catenin/CBP complex maintains survivin transcription in β-catenin deficient/depleted cancer cells
    Yong mi Kim
    Childrens Hospital Los Angeles, Department of Pediatrics, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA
    Curr Cancer Drug Targets 11:213-25. 2011
    ..Therefore, we believe that the ability of ICG-001 to block both the CBP/γ-catenin interaction and the CBP/β-catenin interaction may have clinical significance in cancers in which γ-catenin plays a significant transcriptional role...